Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix

Japanese Journal of Clinical Oncology

Volumn 41, Issue 5, 2011, Pages 624-629

  Hwang, Jong Ha ^a   Lim, Myong Cheol ^a   Seo, Sang Soo ^a   Park, Sang Yoon ^a   Kang, Sokbom ^a  

^a National Cancer Center   (South Korea)

Author keywords

Belotecan; Cervical cancer; Chemotherapy; Clinical trial; Progression; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; BELOTECAN; CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FRACTURE; HUMAN; HYPONATREMIA; INFECTION; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; RADICAL HYSTERECTOMY; SEIZURE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELLS; CAMPTOTHECIN; DIGESTIVE SYSTEM; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NERVOUS SYSTEM; RESPIRATORY SYSTEM; SKIN; TOPOISOMERASE I INHIBITORS; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS;

EID: 79955857726     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr017     Document Type: Article

References (24)

1. Bonomi P, Blessing JA, Stehman FB, Disaia PJ, Walton L, Major FJ. Randomized tiral of three cisplatin dose schedules in squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-85.
2. Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, et al. Antitumor activity of 7-[2(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998;21:581-90.
3. Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ, et al. Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann N Y Acad Sci 2000;922:324-5.
4. Kim HS, Park NH, Kang S, Soe SS, Chung HH, Kim JW, et al. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. J Obstet Gynaecol Res 2010;36:86-93.
5. Simon R. Optional two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
6. Muderspach LI, Blessing JA, Levenback C, Moore JL, Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2001;81:213-5.
7. Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000;77:408-14.
8. Fiorica JV, Blessinf JA, Puneky LV, Secord AA, Hoffman JS, Yamada DS, et al. A phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2009;115:285-9.
9. Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vango G, Scambia G. Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 2010;74:163-74.
10. Long HJ, 3rd, Bundy BN, Grendys EC, Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;20:4626-33.
11. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 on Gynecologic Cancers. Gan To Kagaku Ryoho 1991;18:1681-9.
12. Look KY, Blessing JA, Levenback C, Kohler M, Chafe W, Roman LD. A phase II trial of CPT-11 in recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998;70:334-8.
13. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;12:625-31.
14. Lhomme C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999;17:3136-42.
15. Yu NY, Conway C, Pena RL, Chen JY. STEALTH liposomal CKD 602, a topoisomerase I inhibitor improve the therapeutic index in human tumor xenograft models. Anticancer Res 2007;127:2541-5.
16. Park IS, Ahn MR, Suh SK, Choi HS, Sohn SJ, Yang JS, et al. In vitro pharmacodynamics of CKD-602 in HT-29 cells. Arch Pharm Res 2002;25:718-23.
17. Lee DH, Kim SW, Suh C, Lee JS, Lee JH, Lee SJ, et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2008;19:123-7.
18. Kim SJ, Kim JS, Kim SC, Kim YK, Kim YK, Kang JY, et al. A multicenter phase II study of belotecan, new camptothecin analogue, in patients previously untreated extensive stage disease small cell lung cancer. Lung Cancer 2010;68:446-9.
19. Lee HP, Seo SS, Ryu SY, Kim JH, Bang YJ, Park SY, et al. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 2008;109:359-63.
20. Lee DH, Kim SW, Suh C, Lee JS, Anh JS, Ahn MJ, et al. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naïve patients with extensive-disease small cell lung cancer. Cancer 2010;116:132-6.
21. Lee DH, Kim SW, Bae KS, Hong JS, Suh S, Kang YK, et al. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. Clin Cancer Res 2007;15:6182-6.
22. Nam EJ, Kim JW, Kim JH, Kim S, Kim SW, Jang SY, et al. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. Am J Clin Oncol 2010;33:233-7.
23. Kim HS, Kang SB, Seo SS, Han SS, Kim JW, Park NH, et al. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer. Ann N Y Acad Sci 2009;1171:627-34.
24. Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 2009;76:315-21.